Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma:a single-institution experience  

作　　者：CONSTANTINE N.LOGOTHETIS NATHAN P.HORVAT TONY KURIAN CELESTE BELLO JULIO CHAVEZ LEIDY ISENALUMHE BIJAL SHAH LUBOMIR SOKOL HAYDER SAEED JAVIER PINILLA SAMEH GABALLA 

机构地区：[1]Department of Internal Medicine,University of South Florida,Tampa,FL,33602,USA [2]College of Medicine,University of South Florida Morsani,Tampa,FL,33602,USA [3]H.Lee Moffitt Cancer Center and Research Institute,Tampa,FL,33612,USA

出　　处：《Oncology Research》2024年第6期1031-1036,共6页肿瘤学研究（英文）

摘　　要：Extranodal marginal zone lymphoma(EMZL)encompasses 70%of cases of marginal zone lymphoma.Frontline bendamustine and rituximab(BR)were derived from trials involving other indolent non-Hodgkin’s lymphomas.Only one trial has evaluated frontline BR prospectively in EMZL.This retrospective study reports outcomes among EMZL patients receiving frontline BR.Twenty-five patients were included with a median age of 69 years(40–81).Five(20.0%)patients had stage Ⅰ/Ⅱ disease,and 20(80.0%)had stage Ⅲ/Ⅳ disease.The median number of cycles was 6.0(3.0–6.0).Maintenance rituximab was administered to 10(41.7%)individuals.Overall response rate(ORR)was 100.0%(60.0%complete response,40.0%partial response).Medians of overall survival and progression-free survival were not reached.The estimated 2-year progression-free survival was 85.2%and overall survival was 100.0%.Four(16.6%)patients had infections related to treatment;3(12.0%)transformed to diffuse large B-cell lymphoma;5(20.8%)had a relapse or progression of EMZL;and 3(12.0%)died unrelated to BR.BR is an efficacious and well-tolerated front-line regimen for EMZL with response data consistent with existing literature.

关 键 词：Extranodal marginal zone lymphoma BENDAMUSTINE RITUXIMAB Front-line therapy 

分 类 号：R733.4[医药卫生—肿瘤]